U.S. Markets open in 6 hrs 40 mins

CEL-SCI, Ergomed sign co-development for Multikine

CEL-SCI announced that it has signed a co-development and profit sharing agreement with Ergomed Clinical Research for CEL-SCI’s investigational immunotherapy drug Multikine in HIV/HPV co-infected men and women with peri-anal warts. CEL-SCI has also recently entered a Cooperative Research and Development Agreement for this disease indication with the US Naval Medical Center. Under the terms of this new agreement, Ergomed will assume 50% of the clinical and regulatory costs for the development of Multikine as a potential treatment for HIV/HPV co-infected men and women with peri-anal warts. The full co-development program for Multikine must be jointly agreed to prior to implementation.